Pfizer has made the “difficult decision” to draw a line under its biosimilar endeavors in China, agreeing to sell its biologics manufacturing site in Hangzhou to local biologics contract development and manufacturing firm WuXi Biologics and halt its biosimilar programs in the country.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?